Lactulose breath test predicts Xifaxan response in IBS-D

Patients with diarrhea-predominant irritable bowel syndrome who had a positive baseline result from a lactulose breath test were more likely to respond to Xifaxan therapy, according to results of open-label study.Ali Rezaie, MD, medical director of the GI motility program at Cedars-Sinai Medical Center, and colleagues wrote that like other IBS therapies, Xifaxan (rifaximin, Salix) can be effective, but the ability to determine response is limited.“One goal of therapy should be a tailored approach to the management of IBS,” they wrote. “A goal of maximizing symptomRead More

Share on facebook
Share on twitter
Share on linkedin